hero image
Carey K. Anders, M.D. - UNC-Chapel Hill. Raleigh-Durham, NC, US

Carey K. Anders, M.D. Carey K. Anders, M.D.

Associate Professor, Department of Medicine | UNC-Chapel Hill

Raleigh-Durham, NC, UNITED STATES

Dr. Anders is a Lineberger Comprehensive Cancer Center member & associate professor of medicine in the division of hematology and oncology.



Carey K. Anders, M.D. Publication



loading image loading image loading image loading image


Meet Carey Anders, MD HER2+ MBC - Dr. Carey Anders - 2014 MBCN Conference at UNC




Carey K. Anders, MD is an Associate Professor of Medicine at the University of North Carolina (UNC) School of Medicine and an active member of the UNC Lineberger Comprehensive Cancer Center. As a clinician-scientist, she is Section Leader for the UNC Breast Program, Leader of the UNC breast cancer clinical trials program, and co-Director of the multi-disciplinary brain metastases clinic at UNC. Dr. Anders’ translational research program, which spans bench to bedside, focuses on the biology of triple negative breast cancer and brain metastases. She serves as the principal investigator for multiple clinical trials evaluating novel anti-cancer agents to more effectively treat patients with advanced triple negative breast cancer and brain metastases. In parallel, and supported by the UNC Chapel Hill Hematology Oncology K12, NIH/NCI K23, LCCC SPORE and Damon Runyon Clinical Investigator Award, she has developed multiple intracranial breast cancer tumor models to test novel therapies, including small molecule and nanoparticle chemotherapeutics in the laboratory. She is also devoted to uncovering the genetic and genomic underpinnings of triple negative breast cancer and brain metastases using Next Generation Sequencing, the focus of her American Society of Clinical Oncology Advanced Clinical Research Award. Her ultimate goal is to translate preclinical findings into rationally-designed therapeutic strategies to improve survival and enhance quality of life for the many patients facing a diagnosis of triple negative breast cancer brain metastases.

Industry Expertise (5)

Education/Learning Research Health and Wellness Health Care - Services Writing and Editing

Areas of Expertise (9)

Breast Cancer Oncology Higher Education Internal Medicine Medical Education Women's Health Cancer Research Clinical Research Hematology

Accomplishments (2)

Weatherspoon Family Brain Tumor Research Award (2011) (professional)

The Weatherspoon Family Brain Tumor Research Award was created in 2011 to honor Van Weatherspoon of Charlotte. It recognizes his ongoing commitment and years of service to UNC-Chapel Hill and its brain tumor program.

Cancer and Leukemia Group B (CALGB) Young Investigator Award (2008-2009) (professional)

Dr. Anders was the recipient of this award in 2008-2009.

Education (7)

Vanderbilt University: B.A., Psychology/French 1996

University of Pennsylvania: Post-Bacc., Pre-Medical Studies 1997

Brody School of Medicine, East Carolina University: M.D., Medicine 2002

Duke University Medical Center: Residency, Internal Medicine 2005

American Board of Internal Medicine: Board Certification in Internal Medicine, Internal Medicine 2005

Duke University Medical Center: Fellow, Hematology/Oncology 2008

American Board of Internal Medicine: Board Certification in Medical Oncology, Medical Oncology 2008

Affiliations (2)

  • American Society of Clinical Oncology : Member
  • American Association of Cancer Research: Member

Media Appearances (4)

Subgroup of Women with HER-2-Positive Breast Cancer Highly Sensitive to Treatments, Study Finds

Newswise  online


"Using molecular profiling of patients’ breast cancer tumors, a National Cancer Institute-sponsored study led by UNC Lineberger Comprehensive Cancer Center researchers has identified a group of women with HER2-positive breast cancer who may benefit from less intensive treatment at the outset."

Dr. Anders is featured in this article.

view more

Combined Drug Strategy May Improve Survival Rates in Breast Cancer Patients With Brain Metastasis

Breast Cancer News  online


"Findings from a recent pre-clinical study published in the journal Molecular Cancer Therapeutics may offer a promising drug strategy to improve survival in patients with aggressive breast cancer who are diagnosed with brain metastasis."

The article features the research of Dr. Anders.

view more

Research Shows Advantage to Nanotech Delivery of Therapy for Breast Cancer Brain Metastases

NewsWise  online


“To our knowledge this study is the first of its kind in brain cancer metastases and offers an informed foundation for the development of early-phase clinical trials. It also offers the potential to improve the current treatment paradigm for patients with intracranial breast cancer recurrence.”

Dr. Anders is featured in this article

view more

Reasons for Hope in Metastatic Breast Cancer: A Clinical Context Report

MedPage Today  online


A video and transcript of a conversation between Charles Bankhead of MedPage Today and Dr. Carey Anders.

view more

Event Appearances (5)

Keynote Lecture, “Today’s Research, Tomorrow’s Treatments”

Living Beyond Breast Cancer- Thriving Together: 2016 Conference on Metastatic Breast Cancer  Philadelphia, PA


Multidisciplinary Management of Brain Metastases Arising from Breast Cancer (with Timothy M. Zagar, MD)

Living Beyond Breast Cancer- Thriving Together: 2016 Conference on Metastatic Breast Cancer  Philadelphia, PA


UNC/LCCC Faculty Representative

AACI/AACR/ASCO- Hill Day 2015  Washington, D.C.


Management of HER2+ Metastatic Breast Cancer

UNC Lineberger Comprehensive Cancer Center/Metastatic Breast Cancer Network- 8th Annual Metastatic Breast Cancer Conference  Chapel Hill, NC


Multidisciplinary Management of Bone Metastases Arising from Breast Cancer (with Timothy M. Zagar, MD)

UNC Lineberger Comprehensive Cancer Center/Metastatic Breast Cancer Network- 8th Annual Metastatic Breast Cancer Conference  Chapel Hill, NC


Articles (3)

TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. Breast Cancer in Research and Treatment


Nearly half of patients with advanced triple negative breast cancer (TNBC) develop brain metastases (BM) and most will also have uncontrolled extracranial disease. This study evaluated the safety and efficacy of iniparib, a small molecule anti-cancer agent that alters reactive oxygen species tumor metabolism and penetrates the blood brain barrier, with the topoisomerase I inhibitor irinotecan in patients with TNBC-BM. Eligible patients had TNBC with new or progressive BM and received irinotecan and iniparib every 3 weeks. Time to progression (TTP) was the primary end point; secondary endpoints were response rate (RR), clinical benefit rate (CBR), overall survival (OS), toxicity, and health-related quality of life. Correlative endpoints included molecular subtyping and gene expression studies on pre-treatment archival tissues, and determination of germline BRCA1/2 status. Thirty-seven patients began treatment; 34 were evaluable for efficacy. Five of 24 patients were known to carry a BRCA germline mutation (4 BRCA1, 1 BRCA2). Median TTP was 2.14 months and median OS was 7.8 months. Intracranial RR was 12 %, while intracranial CBR was 27 %. Treatment was well-tolerated; the most common grade 3/4 adverse events were neutropenia and fatigue. Grade 3/4 diarrhea was rare (3 %). Intrinsic subtyping revealed 19 of 21 tumors (79 %) were basal-like, and intracranial response was associated with high expression of proliferation-related genes. This study suggests a modest benefit of irinotecan plus iniparib in progressive TNBC-BM. More importantly, this trial design is feasible and lays the foundation for additional studies for this treatment-refractory disease.

view more

The Prognostic Contribution of Clinical Breast Cancer Subtype, Age and Race among Patients with Breast Cancer Brain Metastases. Cancer



Brain metastases (BM) arising from triple-negative breast cancer (TNBC) portend a poor prognosis. TNBC is more common in premenopausal and African-American (AA) patients; both of these characteristics also confer a poor prognosis. In a single-institution cohort study, the authors attempted to determine whether the inferior outcome noted with TNBC brain metastases is more reflective of a higher risk population or the subtype itself.

The University of North Carolina Breast Cancer Database identified patients with BC brain metastases who were diagnosed between 1988 and 2008. BC subtype was assigned by immunohistochemistry: hormone receptor (HR) positive (+);(HR, estrogen receptor [ER]+ and/or progesterone receptor [PR]+)/human epidermal growth factor receptor 2 (HER2) negative (-), HR+/HER2+, HR-/HER2+, and TN (ER-/PR-/HER2-). Survival and disease recurrence patterns were evaluated by subtype, patient age (

view more

Isolated Cranial Mononeuropathy: An Unusual Initial Presentation and Disease Progression of Metastatic Carcinoma of the Breast Journal of Clinical Oncology


Case Report

A previously healthy 46-year-old woman presented in April 2010 with a 1-month history of right facial paresthesia with pain over the maxillary region. She began receiving carbamazepine for presumed trigeminal neuralgia and experienced some improvement of symptoms. Her neurologic symptoms persisted and she underwent a brain magnetic resonance imaging (MRI) scan that revealed a 2.2 × 1.3 cm mass within Meckel's cave that extended along V2 and V3 branches of the trigeminal nerve; this was concerning for perineural spread of tumor from a nasopharyngeal or salivary gland tumor.

view more